<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271245</url>
  </required_header>
  <id_info>
    <org_study_id>DK58763-c</org_study_id>
    <secondary_id>R01DK058763</secondary_id>
    <secondary_id>DK58763</secondary_id>
    <nct_id>NCT00271245</nct_id>
  </id_info>
  <brief_title>Selenium Supplementation of Patients With Cirrhosis</brief_title>
  <official_title>Selenium Supplementation of Patients With Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether patients with liver cirrhosis can improve
      their selenium nutritional status by taking supplemental selenium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selenium is an essential nutrient. Selenium carries out its biological functions through
      selenoproteins. The liver converts dietary selenium to a form that can be used to make
      selenoproteins. Patients with cirrhosis have much lower selenium levels than healthy
      individuals. We hypothesize that patients with cirrhosis are unable to utilize dietary
      selenium for selenoprotein synthesis. These patients may benefit from another form of
      selenium: selenate.

      We will compare the effects of two supplemental forms of selenium on plasma selenium levels
      in patients with cirrhosis. Patients will be randomized to receive either a placebo, 200 µg
      selenomethionine, 200 µg selenate or 400 µg selenate, daily, for 8 weeks. We will measure
      selenium levels in the blood at baseline, week 4 and week 8. We will determine which forms of
      selenium, if any, increased plasma selenium levels of the cirrhosis patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient funds to complete study.
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma selenoprotein P, Plasma GPX-3 activity, Total plasma selenium</measure>
    <time_frame>8 week</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 µg selenium as selenate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 µg selenium as selenate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 µg selenium as selenomethionine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>200 µg selenium as selenate</intervention_name>
    <description>200 µg selenium as selenate</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>400 µg selenium as selenate</intervention_name>
    <description>400 µg selenium as selenate</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>200 µg selenium as selenomethionine</intervention_name>
    <description>200 µg selenium as selenomethionine</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver disease

          -  aged 18 or above

        Exclusion Criteria:

          -  substance abuse

          -  renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond F Burk, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2005</study_first_submitted>
  <study_first_submitted_qc>December 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2005</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>RBurk</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>liver disease</keyword>
  <keyword>selenium</keyword>
  <keyword>selenoproteins</keyword>
  <keyword>selenoprotein P</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Selenic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

